The promise of once-weekly insulins for type 1 diabetes: update on progress
- PMID: 39306455
- DOI: 10.1016/S0140-6736(24)01917-2
The promise of once-weekly insulins for type 1 diabetes: update on progress
Conflict of interest statement
KML has received research product support from Dexcom and receives grant support from the US National Institutes of Health and the National Institute of Diabetes and Digestive and Kidney Diseases; she has received speaking honorarium from AdventHealth (Orlando, FL, USA). SAB has received research support through her institution from Dexcom, Insulet, Roche, Tandem Diabetes Care, and Tolerion and has participated on a data safety monitoring board for MannKind (non-compensated); she has also received support from the National Institutes of Health and Juvenile Diabetes Research Foundation.
Comment on
-
Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial.Lancet. 2024 Sep 21;404(10458):1132-1142. doi: 10.1016/S0140-6736(24)01804-X. Epub 2024 Sep 10. Lancet. 2024. PMID: 39270686 Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources